Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 269

1.

Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.

Marks JL, McLellan MD, Zakowski MF, Lash AE, Kasai Y, Broderick S, Sarkaria IS, Pham D, Singh B, Miner TL, Fewell GA, Fulton LL, Mardis ER, Wilson RK, Kris MG, Rusch VW, Varmus H, Pao W.

PLoS One. 2007 May 9;2(5):e426.

2.

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, Levine R, Michel K, Thomas RK, Rusch VW, Ladanyi M, Pao W.

Cancer Res. 2008 Jul 15;68(14):5524-8. doi: 10.1158/0008-5472.CAN-08-0099.

3.

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.

Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY.

Cancer Genet Cytogenet. 2007 Mar;173(2):107-13.

PMID:
17321325
4.

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF.

Cancer Res. 2005 Mar 1;65(5):1642-6.

5.

Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.

Conde E, Angulo B, Tang M, Morente M, Torres-Lanzas J, Lopez-Encuentra A, Lopez-Rios F, Sanchez-Cespedes M.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):710-7.

6.

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.

Soung YH, Lee JW, Kim SY, Seo SH, Park WS, Nam SW, Song SY, Han JH, Park CK, Lee JY, Yoo NJ, Lee SH.

Virchows Arch. 2005 May;446(5):483-8. Epub 2005 Apr 7.

PMID:
15815931
7.

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.

Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M.

Clin Cancer Res. 2009 Jul 15;15(14):4554-60. doi: 10.1158/1078-0432.CCR-09-0089. Epub 2009 Jul 7.

8.

PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.

Jin G, Kim MJ, Jeon HS, Choi JE, Kim DS, Lee EB, Cha SI, Yoon GS, Kim CH, Jung TH, Park JY.

Lung Cancer. 2010 Sep;69(3):279-83. doi: 10.1016/j.lungcan.2009.11.012. Epub 2009 Dec 16.

PMID:
20018398
9.

[Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes].

Zhou CC, Zhou SW, Pan H, Su B, Gao ZQ.

Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):119-23. Chinese.

PMID:
17645848
11.

Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.

Shibata T, Hanada S, Kokubu A, Matsuno Y, Asamura H, Ohta T, Sakamoto M, Hirohashi S.

Cancer Sci. 2007 Jul;98(7):985-91. Epub 2007 Apr 23.

12.

Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.

Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC, Zhou HS, Guo BQ.

Clin Cancer Res. 2005 Jun 15;11(12):4289-94.

13.

ERBB2 kinase domain mutation in the lung squamous cell carcinoma.

Lee JW, Soung YH, Kim SY, Nam SW, Park WS, Wang YP, Jo KH, Moon SW, Song SY, Lee JY, Yoo NJ, Lee SH.

Cancer Lett. 2006 Jun 8;237(1):89-94. Epub 2005 Jul 18.

PMID:
16029927
14.
15.

Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors.

Sihto H, Puputti M, Pulli L, Tynninen O, Koskinen W, Aaltonen LM, Tanner M, Böhling T, Visakorpi T, Bützow R, Knuuttila A, Nupponen NN, Joensuu H.

J Mol Med (Berl). 2005 Dec;83(12):976-83. Epub 2005 Aug 31.

PMID:
16133419
16.

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.

Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, Otani Y, Tanaka S, Suga T, Saito R, Ishizuka T, Dobashi K, Minna JD, Nakajima T, Mori M.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6816-22.

18.

Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Lee JC, Lee JE, Kim SY.

Lung Cancer. 2012 Mar;75(3):321-5. doi: 10.1016/j.lungcan.2011.08.005. Epub 2011 Sep 17.

PMID:
21930325
19.

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF.

J Natl Cancer Inst. 2005 Mar 2;97(5):339-46.

20.

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.

Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF.

Clin Cancer Res. 2004 Dec 15;10(24):8195-203.

Items per page

Supplemental Content

Write to the Help Desk